PRNewsWire
16 Jun 2026, 20:44 UTC · 14w ago
Verdict
Headline leans bearish. We score ELTX −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Elicio Therapeutics' Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet its primary disease-free survival endpoint in pancreatic cancer.
So whatThe failure of a lead clinical pipeline candidate typically leads to a massive loss of company valuation and destroys the primary growth thesis for biotech investors.
More negative than 99% of claims this week
Elicio Therapeutics reported Q1 2026 results with zero revenue and a widening net loss.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Law firm SueWallSt has initiated an investigation into Elicio Therapeutics' officers and directors for potentially misleading statements regarding the AMPLIFY-7P program.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company's lead clinical program failed its primary endpoint, shares collapsed by over 72%, and it reported zero revenue with widening losses.
More negative than 79% of ticker scores this week
Shares dropped 17% after the company cut its FY 2026 revenue guidance.
More negative than 73% of ticker scores this week
Investors lost over 10% of holdings following a gap revealed in the Q4 FY 2026 earnings release.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
−32.2%
Price agrees with the score
$1.87 vs $2.76 close before publication (Jun 16) · not market-adjusted
ELTX chart →
